Non-Migratory Tumorigenic Intrinsic Cancer Stem Cells Ensure Breast Cancer Metastasis by Generation of CXCR4 Migrating Cancer Stem Cells
Scientists showed that unlike highly metastatic cancer stem cells (mCSCs) residing in the breast tumor disseminating/peripheral regions, tumorigenic intrinsic CSCs (iCSCs) populate the inner mass of the tumor and are non-migratory. However iCSCs, via paracrine signaling, induce conversion of non-stem cancer cells to CSCs that are identical to the previously reported mCSCs, and in contrast to iCSCs, express chemokine receptor, chemokine receptor 4 (CXCR4), which is crucial for their metastatic potential. [Oncogene] Abstract
The Acetyltransferase Tip60 Contributes to Mammary Tumorigenesis by Modulating DNA Repair
Scientists demonstrated that Tip60 controls homologous recombination (HR)-directed DNA repair, and that Tip60 levels correlate inversely with a gene expression signature associated with defective HR-directed DNA repair. In human breast cancer data sets, Tip60 mRNA was downregulated, with low Tip60 levels correlating with p53 mutations in basal-like breast cancers. [Cell Death Differ] Full Article
Targeting the RB-E2F Pathway in Breast Cancer
Researchers discuss recent advances in understanding of the RB-E2F pathway in breast cancer. They also discuss the application of genome-wide genetic screening efforts to gain insight into synthetic lethal interactions of CDK4/6 inhibitors in breast cancer for the development of more effective combination therapies. [Oncogene] Abstract
Visit our reviews page to see a complete list of reviews in the mammary cell research field.
FDA Approves New Indication for FASLODEX® (Fulvestrant)
AstraZeneca announced that the US Food and Drug Administration (FDA) has approved a new indication expanding the use of FASLODEX® to include use in combination with palbociclib. The combination use is for the treatment of women with hormone receptor-positive, human epidermal growth factor receptor 2 negative advanced or metastatic breast cancer whose cancer has progressed after endocrine therapy. [AstraZeneca] Press Release
Recruit Top Talent: Reach more than 60,000 potential candidates by posting
your organization’s career opportunities on the Connexon Creative Job Board at no cost.
Have we missed an important article or publication in Mammary Cell News? Click here to submit!
